AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03489213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participants will wear a FitBit every day and monitor daily physical activity.
Study NCT03489213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03489213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03489213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Intervention
Description: Participants randomized to the beef group will receive 11 to 18 ounces of frozen lean beef each week for home preparation, in addition to DGA/AICR diet education, garden access and health coaching.
Study NCT03489213 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Participants randomized to the beef group will receive 11 to 18 ounces of frozen lean beef each week for home preparation, in addition to DGA/AICR diet education, garden access and health coaching.
Study NCT03489213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03489213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00599651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surfactant administered via Laryngeal Mask Airway (LMA)
Description: Standard volume of Infasurf surfactant (3 mL/kg) will be injected in 2-4 aliquots into the proximal end of the LMA.
Study NCT00599651 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: standard of care (nasal CPAP and supplemental oxygen)
Description: Standard of care will be utilized which may mean surfactant is administered
Study NCT03114761 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT angiography
Description: Patients are subjected to a standard abdominal CT scan and (additional in this study) to abdominal CT angiography (CTA)
Study NCT03991637 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-Invasive Comprehensive Metabolic Panel
Description: The device utilizes spectroscopy and machine learning to detect metabolic analyte concentrations.
Study NCT03991637 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Invasive Comprehensive Metabolic Panel
Description: The device utilizes spectroscopy and machine learning to detect metabolic analyte concentrations.
Study NCT02317731 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Straw
Description: Bowel preparation ingestion with a straw
Study NCT03216616 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy
Study NCT00479466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0893
Description: MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
Study NCT00479466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin HCL 500 mg tablet twice daily titrating up to 1000 mg twice daily over 3 weeks.
Study NCT00479466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK0893
Description: Dose-matched placebo tablets to MK0893; taken orally once daily.
Study NCT03294213 — intervention group
Intervention type: DEVICE
Intervention: aScope 4 Broncho
Description: Investigator is asked: In your memory, compare your daily bronchoscope and the aScope 4 Broncho just evaluated on patients admitted to the OR or ICU undergoing at least one bronchoscopy procedure Patients will not be asked to consent to participate in this study, as no patient data are obtained and the CE-marked aScope™ 4 Broncho is used within its intended use
Study NCT00479466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK0893
Description: Dose-matched placebo tablets to MK0893; taken orally once daily.
Study NCT00479466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK0893
Description: Dose-matched placebo tablets to MK0893; taken orally once daily.
Study NCT00479466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Metformin
Description: Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
Study NCT00479466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Metformin
Description: Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
Study NCT03426059 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention. This is an observational study.
Study NCT01078753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Desmopressin oral lyophilisate tablet, 120 μg or 240 μg, administered sublingually once a day 1½ hours before bedtime.
Study NCT01078753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral lyophilisate tablet was administered sublingually once a day 1½ hours before bedtime.
Study NCT03543371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological assessment
Description: Standardized neuropsychological battery consisting of the following tests and questionnaires: Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-IV) Vocabulary, Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency, WAIS-IV Block Design, WAIS-IV Matrix Reasoning, WAIS-IV Digit Span, Wechsler Memory Scale - Third Edition (WMS-III) Spatial Span, Rey Auditory Verbal Learning Test (RAVLT), WMS-III Logical Memory, Brief Visuospatial Memory Test-Revised (BVMT-R), Trail Making Test (TMT) A \& B, D-KEFS Color Word Interference Test, Behavioral Assessment of the Dysexecutive Syndrome Dysexecutive Questionnaire (BADS DEX), Multidimensional Fatigue Inventory (MFI-20), Minimal Insomnia Symptom Scale (MISS), Hospital Anxiety and Depression Scale (HADS).
Study NCT01772134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umeclidinium bromide 62.5mcg
Description: Inhalation Powder, LAMA 62.5mcg
Study NCT01772134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Umeclidinium bromide 125mcg
Description: Inhalation Powder, LAMA 125mcg
Study NCT01772134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate 250mcg/Salmeterol 50mcg
Description: Inhalation Powder, ICS/LABA
Study NCT01772134 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate 250mcg/Salmeterol 50mcg
Description: Inhalation Powder, ICS/LABA
Study NCT01772134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 250mcg/Salmeterol 50mcg
Description: Inhalation Powder, ICS/LABA
Study NCT01772134 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation Powder, Placebo
Study NCT03716791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: methylsulfonylmethane
Description: 3g per day
Study NCT03716791 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: white rice flour
Study NCT04339504 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(low-dose)
Description: A single knee administration of SMUP-IA-01(low-dose, 4.0 x 10\^6 cells/2mL)
Study NCT04339504 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(mid-dose)
Description: A single knee administration of SMUP-IA-01(mid-dose, 1.0 x 10\^7 cells/2mL)
Study NCT04339504 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SMUP-IA-01(high-dose)
Description: A single knee administration of SMUP-IA-01(high-dose, 2.0 x 10\^7 cells/2mL)
Study NCT00804856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Study NCT00804856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Low-dose cytarabine (LDAC) 2x20mg per day administered by subcutaneous injection on days 1-10 of each 28 day treatment cycle.
Study NCT01704885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Play Intervention
Study NCT01676194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-arterial administration of DC BeadsR
Study NCT01704885 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Questionnaires
Study NCT03138967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Experimental: Sugammadex Participants to have cystoscopy with bladder tumor resection. Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.
Study NCT03138967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Experimental: Sugammadex Participants to have cystoscopy with bladder tumor resection. Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.45 mg/kg of Ideal Body Weight. If maintenance is needed for continued relaxation then a dose of 0.15 mg/kg of Ideal Body Weight repeated as necessary.
Study NCT03138967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex administered as a single bolus, intravenous injection. The amount used is based on the patient's weight. A dose of 4 mg/kg used if recovery has reached at least 1-2 post-tetanic counts (PTC) following Rocuronium induced blockade.
Study NCT03138967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: 70 mcg/kg by vein to reverse the muscle relaxation.
Study NCT03138967 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: 14 mcg/kg by vein to reverse the muscle relaxation.
Study NCT04376190 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low level laser therapy
Description: In the laser group, patients received LLLT from a semiconductor Gallium Aluminum Arsenide diode laser (SMARTMPRO, LASOTRONIX, Poland) with the following set parameters; 635 nm wavelength in continuous-wave mode, 50 mw power output, 4.5 J/cm2 energy density, 11.25 J total dose per side, 45 seconds/ point, and 8 mm fiber optic tip diameter. Laser was applied (Fig.2) at five points located within TMJ region on both right and left sides in contact with skin as follows: lateral, superior, anterior, posterior, and posterior- inferior points.
Study NCT04736186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)
Study NCT04736186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide and golden bifid
Description: Patients with secondary prevention will be randomly assigned to B：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+golden bifid 2 g t.i.d.
Study NCT01704885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Study NCT00893568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resonance magnetic imaging (fMRI),
Description: a cerebral study will be performed at the neuroanatomic and functional levels by resonance magnetic imaging (fMRI) realized in three times (before, one week and six months after treatment)
Study NCT04736186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide and montmorillonite powder
Description: Patients with secondary prevention will be randomly assigned to D：Loperamide 4 mg， t.i.d.(d 1-7);4 mg, b.i.d.(d 8-21)+montmorillonite powder 3 g t.i.d.
Study NCT06558916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen Trometamol
Study NCT06558916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meperidine Injectable Solution
Study NCT06558916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Study NCT06558916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Patients with a VAS score of 40 mm or higher at the 30th minute were given fentanyl (1 mcg/kg, intravenously) as a rescue drug.
Study NCT00893568 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: resonance magnetic imaging (fMRI),
Description: a cerebral study will be performed at the neuroanatomic and functional levels by resonance magnetic imaging (fMRI) realized in three times (before, one week and six months after treatment)
Study NCT00835692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: 500 mg Tablet
Study NCT00835692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biaxin®
Description: 500 mg Tablet
Study NCT04143022 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture press needle
Description: Press needle will be applied to acupoints at Jin's 3-tongue point ( EX-HN21 and the two extra channel points, 0.8 individual cun lateral to both sides of EX-HN21) and EX-HN25 in group A and at EX-CA1, EX-CA5 and EX-CA6 in group B. Each subject will start first course and receive the treatment 2 times a week for 4 weeks (8 times in total). Then, it takes 2-week washout period and make group A and group B crossover. Second course begins after 2-week washout period with the same treatment times as the first course.
Study NCT02680288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin, 10 mg
Description: Oral type 2C serotonergic agonist, low-dose
Study NCT00377260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin-clavulanate
Description: Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.
Study NCT00377260 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same base formulation of the licensed product Augmentin ES-600™, with the same strawberry cream flavor.
Study NCT03526757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standing Pilates protocol
Description: Subjects will be submitted to a bi-weekly, 50-minute session of Pilates exercises focusing on orthostatic position, for twelve weeks. The following equipment will be used: The Cadillac, Reformer and Chair, emphasizing balance training in the orthostatic position.
Study NCT03526757 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pilates protocol
Description: Subjects will be submitted to a bi-weekly, 50-minute session of the standard sequence of Pilates exercises (traditional sequence of the contemporary / classical method) for twelve weeks. The exercises will be performed using the same equipment used in the intervention group, but following the dorsal decubitus, sedestation and orthostasis, in a time-balanced distribution in each session.
Study NCT02680288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin, 20 mg
Description: Oral type 2C serotonergic agonist, high-dose
Study NCT02680288 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oral Placebo
Description: Oral inert treatment
Study NCT01924377 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard circumferential pulmonary vein isolation by radiofrequency ablation catheter
Description: To perform circumferential pulmonary vein isolation left and right circumferential lines will be created with contiguous focal radiofrequency lesions at a distance >5 mm from the pulmonary vein ostia. Two additional ablation lines will be performed in the posterior left atrium (LA), and an ablation line will be placed in the mitral isthmus to prevent postablation LA flutter. Patients with a history of typical atrial flutter will also undergo cavotricuspid isthmus ablation.
Study NCT01924377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPVI + rotors' identification and ablation
Description: In CPVI + Rotor arm, two LA sequential maps will be collected before and after CPVI, respectively. During each map creation, rotor electrograms will be identified by the physician. Rotors will be ablated after collecting the second LA sequential map.
Study NCT01890057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: The dose of sugammadex
Study NCT01554007 — intervention group
Intervention type: OTHER
Intervention: Observation study
Description: No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
Study NCT01655654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical activity
Description: This intervention includes cardiorespiratory exercise, resistance exercise, flexibility exercise and neuromotor exercise.
Study NCT01655654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary
Description: Make at least one positive dietary change including or similar to a DASH diet snack substitution.
Study NCT01655654 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary care provider visit
Description: Subjects with hypertension will be asked to visit their primary care provider seeking treatment options. If a subject does not have a primary care provider then they will be encouraged to obtain one and seek medical treatment.
Study NCT01895335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Pharmaceutical form: film-coated tablet; Route of administration: oral
Study NCT00191815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).
Study NCT00191815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).
Study NCT02982577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: Spray the basis of 1.54% pilocarpine, 3 times per day (each 8 hours), during 90 days.
Study NCT02982577 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Spray without Pilocarpine
Description: Spray without pilocarpine, 3 times per day (each 8 hours), during 90 days.
Study NCT01294072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention
Description: no treatment
Study NCT04130711 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Visual virtual Conditions
Description: The objective is to evaluate if certain virtual visual conditions can increase the illusion of movement induced by the tendon vibration of the upper limb.~Thirty healthy volunteers and 20 post-stroke subjects will test 3 different situations of vibration applications, with no EEG Neurofeedback session. It will be applied to the subject (healthy and post-stroke) according to a randomized order a vibrator for a few minutes on his non-dominant (or deficit) hand hidden from view, with a screen representing a static virtual hand, then a vibrator on his hand hidden with a screen representing an animated virtual hand, then a vibrator on his hand hidden with a screen representing an empty background.
Study NCT04130711 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard EEG
Description: Twenty healthy volunteers test 3 separate electroencephalographic recording conditions without Neurofeedback. It will be applied to the subject an EEG headset recording brain activity during the application of vibration stimulation producing the illusion of movement on the non-dominant hand or during a task Mental imagery of the upper limb, or during the joint application of vibratory stimulation and a mental imaging task on the affected upper limb in a randomized order.
Study NCT03352362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen (caldolor 10 mg / kg)
Description: Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia
Study NCT03352362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propacetamol (denogan 30 mg / kg)
Description: Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
Study NCT03352362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen + propacetamol
Description: Dilution caldolor 10 mg / kg in Hartmann solution to 50 mL - 100 mL and intravenous injection for 30 minutes immediately after induction of anesthesia Dilution denogan 30 mg / kg in the dissolved solution to a total of 10 ml and intravenous injection for 10 minutes after the main surgical procedure end
Study NCT04802694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Water-based barrier tape
Description: The infants in experiment 1 group will be applied water-based barrier tape. The area will be covered by water-based barrier tape to fix nasogastric tube and after waiting 1 minute for drying up it will be fastened by silk tape used in clinic. The silk tape will be 5 cm long and it will be changed in every 24 hours. Following the removal of silk tape on the water-based barrier tape, the skin integrity of the infants will be evaluated through Neonatal Skin Condition Score Scale and the score will be recorded in the chart. Water-based barrier tape will be applied to the area every time the plaster will be changed and current skin condition score will be noted to the chart.